Caren van Roekel

91 Quality of life in patients treated with 166 Ho-radioembolization TABLE 1. Overview of literature (continued) First author, year Treatment arm Control arm n (Y-RE/ other) Primary tumor(s) RE approach Questionnaires Scale range Timing Outcome Cramer, 2016 (23) Y-RE - 30 Neuroendocrine tumour Lobar Short Form-36 Health Survey Form 0-100 Baseline, 1,3,6,12,24 months QoL was sustained for up to 24 months following treatment Vilgrain, 2019 (28) Y-RE Sorafenib 184/206 HCC 205 lobar treatments, 81 segmental/ sector treatments QLQ-C30, EORTC-HCC18 0-100 Baseline, 1 month, 3-monthly (up to 12 months) Global health status was significantly better in the Y-RE group than in the sorafenib group Kirchner, 2018 (25) Y-RE TACE 21/46 HCC NR QLQ-C30, EORTC-HCC18 0-100 Baseline, 2 weeks QoL was not significantly affected and there was no significant difference between groups Gill, 2018 (26) Y-RE TACE, sorafenib HCC NR Online survey NR NR QoL improved after RE and TACE compared to sorafenib Xing, 2018 (27) Y-RE - 30 HCC Lobar Short Form-36 Health Survey Form 0-100 Baseline, 1, 3, 6 months No significant changes in QoL Y-RE + chemo Gray, 2001 (20) Y-RE & 5-FU 5-FU e 36/34 Colorectal Whole liver Self Assessment Scale Baseline, 3-monthly (up to 18 months) No significant difference, in both arms QoL tended to improve 3